--- title: "Oncolytics Biotech (ONCY) news: going concern and Nasdaq notice" url: "https://aibio.space/companies/oncolytics-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ONCY going concern and Nasdaq notice news: Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027." --- ONCY Oncolytics Biotech Inc. NASDAQ · United States # Oncolytics Biotech (ONCY) news ONCY going concern and Nasdaq notice news Listings · 2026-07-24 ## [Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027](https://aibio.space/news/oncolytics-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Nasdaq told Oncolytics its stock closed below $1.00 for 30 consecutive business days. The letter does not change the listing for now, but the company's annual report says its $5.2 million of cash cannot fund planned operations for 12 months, and that doubt about its ability to continue as a going concern is substantial. ## Latest Oncolytics Biotech news 1. 2025-05-14 Financings [Oncolytics Biotech flags going concern doubt in first-quarter statements](https://aibio.space/news/oncolytics-biotech-flags-going-concern-doubt-first-quarter-statements/) Oncolytics had cash of 15,303 thousand Canadian dollars at March 31, 2025, and said it can fund operations through the third quarter of 2025. ## Oncolytics Biotech at a glance - **Ticker**: ONCY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $4.1 million ### Related companies - [CERo Therapeutics Holdings](https://aibio.space/companies/cero-therapeutics/) OTC: CERO - [Generate Biomedicines](https://aibio.space/companies/generate-biomedicines/) NASDAQ: GENB - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) AMEX: LCTX - [Prime Medicine](https://aibio.space/companies/prime-medicine/) NASDAQ: PRME - [Geron](https://aibio.space/companies/geron/) NASDAQ: GERN - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) AMEX: MAIA - [Neutra](https://aibio.space/companies/neutra/) OTC: NTRR ### Also on NASDAQ - [ICU MEDICAL INC/DE](https://aibio.space/companies/icu-medical-de/) ICUI - [Ceribell](https://aibio.space/companies/ceribell/) CBLL - [Natera](https://aibio.space/companies/natera/) NTRA - [Immunovant](https://aibio.space/companies/immunovant/) IMVT - [Propanc Biopharma](https://aibio.space/companies/propanc-biopharma/) PPCB - [Jin Medical International](https://aibio.space/companies/jin-medical-international/) ZJYL ## What Oncolytics Biotech does Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep is a proprietary isolate of reovirus that selectively replicates in RAS-mutated tumors and is described as activating innate and adaptive immune responses. The company says it is positioning pelareorep as a platform immunotherapy for gastrointestinal cancers, with the aim of advancing its GI programs to registration-enabled clinical studies. Combinations under study include chemotherapies, checkpoint inhibitors, CAR T therapies, bispecific antibodies, and RAS or CDK4/6 inhibitors. The company names metastatic colorectal cancer, second-line or later anal cancer, and metastatic pancreatic cancer as areas it is exploring for registrational programs. More than 1,600 patients have received at least one dose of study treatment with pelareorep in clinical studies. The company expects to pursue strategic alliances with larger companies for later development. The filing also states that there is substantial doubt about the company's ability to continue as a going concern. | Product or program | What it is | Stage | |---|---|---| | Pelareorep | Intravenous reovirus isolate for RAS-mutated and GI tumors | clinical-stage | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/oncy-20251231.htm). ## Oncolytics Biotech annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$13.3 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | [$15.4 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | | Net income (loss) | [-$28.8 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | [-$22.8 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | | Cash from operations | [-$20.1 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | | Cash and equivalents | [$5.2 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000051/) | [$11.1 million](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Analysis - Opinion Negative view 2026-10-28 [Oncolytics has about two months of cash at its average burn](https://aibio.space/analysis/oncolytics-has-about-two-months-cash-average-burn/) Cash of $4.1 million covers about two months at average burn, and the company's own going concern language points the same way. Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/). ## Questions about Oncolytics Biotech Has Oncolytics Biotech issued a going-concern warning? Our latest story on this, dated Jul 24, 2026: "Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oncolytics-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). Has Oncolytics Biotech received a Nasdaq deficiency notice? Our latest story on this, dated Jul 24, 2026: "Oncolytics Biotech gets Nasdaq minimum bid price deficiency notice, has until January 19, 2027". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/oncolytics-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). What is the ticker symbol of Oncolytics Biotech? Oncolytics Biotech Inc. trades under the ticker ONCY on NASDAQ. Where is Oncolytics Biotech listed? Oncolytics Biotech Inc. is listed on NASDAQ. What is the SEC CIK of Oncolytics Biotech? The SEC Central Index Key (CIK) for Oncolytics Biotech Inc. is 1129928. Its filings are on SEC EDGAR. How many shares does Oncolytics Biotech have outstanding? 127,510,505 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Oncolytics Biotech listed under? Our directory records Oncolytics Biotech Inc. under United States. What does Oncolytics Biotech do? Our directory classifies Oncolytics Biotech Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Oncolytics Biotech? The ISIN recorded for Oncolytics Biotech Inc. is US68237V1035. Does aibio.space cover Oncolytics Biotech? aibio.space lists Oncolytics Biotech Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Oncolytics Biotech incorporated? SEC records list its state or country of incorporation as NV. What does Oncolytics Biotech develop? Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep is a proprietary isolate of reovirus that selectively replicates in RAS-mutated tumors and is described as activating innate and adaptive immune responses. What is Pelareorep from Oncolytics Biotech? Pelareorep: Intravenous reovirus isolate for RAS-mutated and GI tumors Stage: clinical-stage. Is Oncolytics Biotech profitable? Oncolytics Biotech Inc. reported a net loss of $28.8 million for the fiscal year ended Dec 31, 2025, and used $20.1 million of cash in operations, per its annual report to the SEC. How much does Oncolytics Biotech spend on research and development? $13.3 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Oncolytics Biotech Members talk about Oncolytics Biotech (ONCY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Oncolytics Biotech, newest first. Each line links the filing it comes from. 1. 2026-07-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000047/oncy-20260720.htm) 2. 2026-07-08 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/tm2620055d1_8k.htm) 3. 2026-04-06 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000110465926039932/tm2610715d3_424b5.htm) 4. 2026-03-30 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000020/oncy-20251231.htm) 5. 2026-01-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1129928/000110465926003815/tm263244d1_ex99-1.htm) 6. 2025-11-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000089/ex991-interimfsseptember30.htm) 7. 2025-10-20 Mergers Filed documents for a merger or acquisition. SEC Form F-4. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000110465925100534/tm2528979d1_f4.htm) 8. 2025-10-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000110465925100414/tm2528785d1_424b5.htm) 9. 2025-08-08 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000062/ex991-interimfsjune302025.htm) 10. 2025-08-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000064/form6ktsxdelisting.htm) 11. 2025-05-14 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992825000034/ex991-interimfsmarch312025.htm) 12. 2024-11-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1129928/000112992824000071/ex991-interimfsseptember30.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ONCY on TradingView](https://www.tradingview.com/symbols/NASDAQ-ONCY/). ## SEC filings and registration - **SEC name**: Oncolytics Biotech Inc - **CIK**: 1129928 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ONCY (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 - **Phone**: 4036707377 - **Shares outstanding**: 127,510,505 as of 2026-08-10 (10-Q filed 2026-08-12) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000074/oncy-20261020.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000072/oncy-20261014.htm) filed 2026-10-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000070/oncy-20261012.htm) filed 2026-10-13 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000066/oncy-20261002.htm) filed 2026-10-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000059/oncy-20260929.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000057/oncy-20260928.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000055/oncy-20260910.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1129928/000112992826000053/oncy-20260818.htm) filed 2026-08-18 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001129928), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Oncolytics Biotech Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ONCY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Oncolytics Biotech Inc. - **Ticker**: ONCY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US68237V1035 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-ONCY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/oncolytics-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Oncolytics Biotech (ONCY) news: going concern and Nasdaq notice", 2026-10-31, https://aibio.space/companies/oncolytics-biotech/